Search
Dengue virus serotype 1
go.drugbank.com/drugs/DB22664Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Magnesium salicylate
go.drugbank.com/drugs/DB01397ApprovedIt is available in several over-the-counter (OTC) formulations.
Antazoline
go.drugbank.com/drugs/DB08799ApprovedIt is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.
Synonyms: 2-(N-Phenyl-N-benzylaminomethyl)imidazoline, 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamineR-30490
go.drugbank.com/drugs/DB09179ExperimentalR-30490 is an opioid related to carfentanil used as an animal tranquilizer. … R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely
Benactyzine
go.drugbank.com/drugs/DB09023ApprovedWithdrawnBenactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety. … Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Benperidol
go.drugbank.com/drugs/DB12867ApprovedWithdrawnBenperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
SP1049C
go.drugbank.com/drugs/DB04978Experimental[A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. … Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus.
Categories: Compounds used in a research, industrial, or household settingArundic acid
go.drugbank.com/drugs/DB05343InvestigationalArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalVLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD). … It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease).
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.